Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 2
2015 3
2016 2
2017 2
2018 1
2020 2
2021 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials.
Core JQ, Pistilli M, Hua P, Daniel E, Grunwald JE, Toth CA, Jaffe GJ, Martin DF, Maguire MG, Ying GS; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Core JQ, et al. Ophthalmol Retina. 2022 Sep;6(9):771-785. doi: 10.1016/j.oret.2022.03.024. Epub 2022 Apr 9. Ophthalmol Retina. 2022. PMID: 35405352 Free PMC article. Clinical Trial.
DESIGN: Cohort within a randomized clinical trial. PARTICIPANTS: Participants in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) assigned to PRN treatment. ...
DESIGN: Cohort within a randomized clinical trial. PARTICIPANTS: Participants in the Comparison of Age-related Macular Degeneration T …
Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Daniel E, et al. Ophthalmology. 2016 Mar;123(3):609-16. doi: 10.1016/j.ophtha.2015.10.034. Epub 2015 Dec 8. Ophthalmology. 2016. PMID: 26681392 Free PMC article. Clinical Trial.
PURPOSE: To compare baseline characteristics, visual acuity (VA), and morphologic outcomes between eyes with retinal angiomatous proliferation (RAP) and all other eyes among patients with neovascular age-related macular degeneration (NVAMD) treated with anti-vascular endothelial …
PURPOSE: To compare baseline characteristics, visual acuity (VA), and morphologic outcomes between eyes with retinal angiomatous proliferati …
Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials.
Core JQ, Hua P, Daniel E, Grunwald JE, Jaffe G, Maguire MG, Ying GS; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Core JQ, et al. Br J Ophthalmol. 2023 Jul;107(7):1000-1006. doi: 10.1136/bjophthalmol-2021-320665. Epub 2022 Apr 15. Br J Ophthalmol. 2023. PMID: 35428655 Free PMC article.
This study aims to determine the association between thiazolidinedione usage and retinal morphological outcomes or visual acuity (VA) in patients treated with bevacizumab or ranibizumab for neovascular AMD (nAMD). METHODS: Secondary analysis of data from the Comparison of …
This study aims to determine the association between thiazolidinedione usage and retinal morphological outcomes or visual acuity (VA) in pat …
Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL 3rd, Fine SL, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Comparison of Age-related Macular Degeneration Treatments Trials CATT Research Group. Altaweel MM, et al. Ophthalmology. 2015 Feb;122(2):391-398.e5. doi: 10.1016/j.ophtha.2014.08.020. Epub 2014 Oct 11. Ophthalmology. 2015. PMID: 25307130 Free PMC article. Clinical Trial.
OBJECTIVE: To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50% of the lesion composed of blood (B50 group) versus all other eyes (Other group) enrolled in the Comparison of Age-Related Macular Degenera …
OBJECTIVE: To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50% of th …
Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials.
Xue K, Hua P, Maguire MG, Daniel E, Jaffe GJ, Grunwald JE, Ying GS; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Xue K, et al. Ophthalmol Retina. 2023 Jul;7(7):564-572. doi: 10.1016/j.oret.2023.02.008. Epub 2023 Feb 19. Ophthalmol Retina. 2023. PMID: 36803692 Clinical Trial.
VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).
Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Hagstrom SA, et al. JAMA Ophthalmol. 2014 May;132(5):521-7. doi: 10.1001/jamaophthalmol.2014.109. JAMA Ophthalmol. 2014. PMID: 24652518 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: In total, 835 of 1149 patients (72.7%) participating in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) at 43 CATT clinical centers. ...The method of controlling the false discovery rate was used to adjust for …
DESIGN, SETTING, AND PARTICIPANTS: In total, 835 of 1149 patients (72.7%) participating in the Comparison of Age-Related Macular Dege …
Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Finn AP, Pistilli M, Tai V, Daniel E, Ying GS, Maguire MG, Grunwald JE, Martin DF, Jaffe GJ, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Finn AP, et al. Am J Ophthalmol. 2021 Mar;223:338-347. doi: 10.1016/j.ajo.2020.11.002. Epub 2020 Nov 19. Am J Ophthalmol. 2021. PMID: 33221285 Free PMC article. Clinical Trial.
SETTING: Multicenter clinical trial. PATIENT POPULATION: 68 eyes from the Comparison of Age-Related Macular Degeneration Treatments Trials. INTERVENTION: Treatment with anti-vascular endothelial growth factor agents. ...
SETTING: Multicenter clinical trial. PATIENT POPULATION: 68 eyes from the Comparison of Age-Related Macular Degeneration Treatments T …
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Writing Committee:; Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, et al. Ophthalmology. 2020 Apr;127(4S):S135-S145. doi: 10.1016/j.ophtha.2020.01.029. Ophthalmology. 2020. PMID: 32200813 Clinical Trial.
Visual and Morphologic Outcomes in Eyes with Hard Exudate in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Daniel E, Grunwald JE, Kim BJ, Maguire MG, Jaffe GJ, Toth CA, Ferris FL 3rd, Martin DF, Shaffer J, Ying GS; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Daniel E, et al. Ophthalmol Retina. 2017 Jan-Feb;1(1):25-33. doi: 10.1016/j.oret.2016.09.001. Ophthalmol Retina. 2017. PMID: 28620652 Free PMC article.
PURPOSE: To compare baseline characteristics, visual acuity (VA) and morphological outcomes between eyes with baseline hard exudates (HE) and all other eyes among patients with neovascular age-related macular degeneration (NVAMD) treated with anti-vascular endothelial growth fact …
PURPOSE: To compare baseline characteristics, visual acuity (VA) and morphological outcomes between eyes with baseline hard exudates (HE) an …
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, et al. Ophthalmology. 2016 Aug;123(8):1751-1761. doi: 10.1016/j.ophtha.2016.03.045. Epub 2016 May 2. Ophthalmology. 2016. PMID: 27156698 Free PMC article. Clinical Trial.
DESIGN: Cohort study. PARTICIPANTS: Patients enrolled in the Comparison of AMD Treatments Trials. METHODS: Patients were assigned randomly to ranibizumab or bevacizumab and to 1 of 3 dosing regimens. ...
DESIGN: Cohort study. PARTICIPANTS: Patients enrolled in the Comparison of AMD Treatments Trials. METHODS: Patients were assigned ran …
14 results